Vimta Labs Ltd
Incorporated in 1990, Vimta Labs Ltd is a contract research and testing services provider[1]
- Market Cap ₹ 1,699 Cr.
- Current Price ₹ 765
- High / Low ₹ 805 / 390
- Stock P/E 33.4
- Book Value ₹ 152
- Dividend Yield 0.26 %
- ROCE 16.8 %
- ROE 12.9 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 8.03% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Part of BSE Allcap BSE SmallCap BSE Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
109 | 127 | 116 | 138 | 154 | 183 | 213 | 181 | 209 | 276 | 315 | 313 | 315 | |
88 | 101 | 99 | 119 | 127 | 138 | 155 | 151 | 156 | 196 | 222 | 229 | 216 | |
Operating Profit | 21 | 26 | 17 | 19 | 27 | 45 | 58 | 30 | 53 | 80 | 94 | 84 | 98 |
OPM % | 19% | 20% | 15% | 14% | 18% | 25% | 27% | 17% | 25% | 29% | 30% | 27% | 31% |
1 | 3 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 0 | 3 | 4 | -1 | |
Interest | 3 | 2 | 1 | 1 | 2 | 5 | 5 | 4 | 2 | 2 | 3 | 2 | 2 |
Depreciation | 15 | 9 | 11 | 10 | 10 | 16 | 20 | 21 | 23 | 23 | 31 | 34 | 33 |
Profit before tax | 4 | 18 | 7 | 8 | 17 | 26 | 35 | 8 | 28 | 55 | 64 | 52 | 63 |
Tax % | 4% | 25% | 24% | 23% | 36% | 36% | 28% | 17% | 25% | 26% | 26% | 25% | |
4 | 13 | 5 | 6 | 11 | 16 | 25 | 7 | 21 | 41 | 47 | 39 | 47 | |
EPS in Rs | 1.90 | 5.99 | 2.29 | 2.91 | 4.79 | 7.43 | 11.45 | 3.13 | 9.62 | 18.57 | 21.37 | 17.51 | 21.42 |
Dividend Payout % | 32% | 33% | 44% | 34% | 0% | 27% | 17% | 0% | 21% | 11% | 9% | 11% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 8% |
3 Years: | 14% |
TTM: | 4% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 9% |
3 Years: | 22% |
TTM: | 22% |
Stock Price CAGR | |
---|---|
10 Years: | 25% |
5 Years: | 50% |
3 Years: | 30% |
1 Year: | 79% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 14% |
3 Years: | 17% |
Last Year: | 13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
Reserves | 108 | 116 | 118 | 122 | 132 | 148 | 167 | 169 | 190 | 229 | 276 | 312 | 334 |
12 | 7 | 4 | 26 | 44 | 40 | 26 | 32 | 30 | 19 | 15 | 19 | 12 | |
21 | 22 | 21 | 23 | 42 | 40 | 40 | 39 | 49 | 54 | 65 | 61 | 85 | |
Total Liabilities | 145 | 149 | 146 | 176 | 222 | 232 | 237 | 245 | 273 | 306 | 360 | 396 | 435 |
93 | 90 | 88 | 88 | 88 | 140 | 135 | 131 | 128 | 162 | 168 | 163 | 175 | |
CWIP | 0 | 2 | 0 | 6 | 53 | 0 | 4 | 2 | 17 | 0 | 12 | 59 | 75 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 6 | 6 | 6 | 6 |
51 | 57 | 58 | 82 | 80 | 92 | 99 | 105 | 122 | 138 | 174 | 168 | 179 | |
Total Assets | 145 | 149 | 146 | 176 | 222 | 232 | 237 | 245 | 273 | 306 | 360 | 396 | 435 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
16 | 17 | 15 | -1 | 24 | 33 | 39 | 24 | 37 | 59 | 87 | 59 | |
-4 | -8 | -8 | -16 | -39 | -24 | -16 | -20 | -32 | -38 | -57 | -75 | |
-11 | -8 | -9 | 19 | 13 | -8 | -23 | -1 | -5 | -16 | -11 | -2 | |
Net Cash Flow | 1 | 0 | -1 | 2 | -2 | 1 | 1 | 3 | 1 | 5 | 19 | -17 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 87 | 81 | 82 | 100 | 101 | 111 | 100 | 117 | 128 | 102 | 93 | 101 |
Inventory Days | 165 | 175 | 158 | 213 | 183 | 209 | 199 | 191 | 140 | 115 | 187 | 185 |
Days Payable | 147 | 87 | 66 | 77 | 184 | 148 | 115 | 114 | 139 | 81 | 119 | 61 |
Cash Conversion Cycle | 105 | 169 | 174 | 236 | 100 | 172 | 184 | 194 | 128 | 136 | 160 | 224 |
Working Capital Days | 88 | 84 | 120 | 126 | 68 | 88 | 87 | 100 | 116 | 96 | 84 | 102 |
ROCE % | 6% | 16% | 6% | 7% | 11% | 17% | 21% | 6% | 14% | 24% | 24% | 17% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
12 Nov - Transcript of the H1/Q2-2024-25 earnings/investor call held on 08th November 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
9 Nov - Audio recording of Q2-FY 2024-25 earnings call available.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Nov - Standalone and Consolidated Unaudited Financial Results for the 2nd Quarter/Half Year ended 30th September 2024, Published in Financial Express (English) and Nava Telangana (Telugu) on …
-
Announcement under Regulation 30 (LODR)-Investor Presentation
8 Nov - Investor presentation for Q2 results FY 2024-25.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
8 Nov - Vimta Labs reports Q2 FY25 financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Oct 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Jun 2020TranscriptPPT
-
Feb 2020TranscriptPPT
-
Nov 2019TranscriptPPT
Business Overview:[1]
VLL is is in the business of contract research and testing in the fields of biologics, small molecules, agro -chemicals, food & beverages, electronics, clinical diagnostics, medical devices, home and personal care products, and environment testing